glp-1 receptor agonist use and risk of suicide death Frontiers Glucagon-like peptide-1 receptor agonists and

This creates a fundamentally different metabolic profile

Subsequently, Lamers et al

Irrespective of whether a patent in a patent family was a continuation, continuation-in-part, divisional application, or linked by a terminal disclaimer in terms of its expiry date, it was counted as a distinct patent

doi: 10.1111/jdi.12063 61 ZhaoYYChenLHHuangLLiYZYangCZhuYet al

At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial